We are live on ! Find out more
TGI

TRV GP III Portfolio holdings

AUM $6.14M
1-Year Est. Return 45.44%
This Fund
S&P 500
This Quarter Est. Return
+2.82%
1 Year Est. Return
+45.44%
3 Year Est. Return
+169.98%
5 Year Est. Return
+802.39%
10 Year Est. Return
–
AUM
$1.16B
AUM Growth
-$26.1M
Cap. Flow
-$39.5M
Cap. Flow %
-3.4%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
1
Closed
–
Avg Time Held
5.1 quarters
Top 10 Avg Time Held
5.1 quarters
Top 20 Avg Time Held
5.1 quarters

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$39.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RLAY icon
1
Relay Therapeutics
RLAY
$3.92B
$439M 37.66%
10,551,115
– –
2020 Q3
1 quarter
RVMD icon
2
Revolution Medicines
RVMD
$40.7B
$278M 23.88%
7,024,031
-1,000,000
-12% -$39.5M
2020 Q1
3 quarters
NRIX icon
3
Nurix Therapeutics
NRIX
$2.32B
$178M 15.31%
5,422,549
– –
2020 Q3
1 quarter
PLRX icon
4
Pliant Therapeutics
PLRX
$63.2M
$133M 11.39%
5,839,160
– –
2020 Q2
2 quarters
FULC icon
5
Fulcrum Therapeutics
FULC
$288M
$69.8M 6%
5,962,202
– –
2019 Q3
5 quarters
VYGR icon
6
Voyager Therapeutics
VYGR
$151M
$45.7M 3.92%
6,391,176
– –
2017 Q4
12 quarters
JNCE
7
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$21.3M 1.83%
3,048,780
– –
2017 Q4
12 quarters

Similar funds

TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

TRV GP III's Q4 2020 Portfolio in Review

As of Q4 2020, TRV GP III held 7 positions worth $1.16B, down 2.2% from $1.19B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP III withdrew a net $39.5M in Q4 2020, reducing 1 holding. Its largest reduction was Revolution Medicines, cutting an estimated $39.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP III's biggest Q4 2020 reduction was Revolution Medicines, cutting an estimated $39.5M.
  • TRV GP III's ten largest holdings make up 100% of its $1.16B portfolio in Q4 2020.
  • TRV GP III opened 0 new positions and closed 0 in Q4 2020.
  • TRV GP III's portfolio value fell 2.2% quarter-over-quarter to $1.16B.

Based on TRV GP III's 13F filing for Q4 2020, filed 16 Feb 2021.